Grassi V, Nicora M, Beretta A
Chair of Respiratory Physiopathology, University of Perugia, Italy.
Int J Clin Pharmacol Res. 1987;7(5):337-44.
In this study the effectiveness and safety of a new controlled-release theophylline formulation were evaluated. Twenty patients (12 male, 8 female) affected by bronchial asthma (mean age 45 years) or chronic obstructive lung disease (mean age 58 years) were given the drug. During the 30 days of controlled-release theophylline therapy, all patients reported a marked clinical improvement, confirmed by spirometric data (ventilation indexes, intrapulmonary air distribution, ventilation control, gas exchanges). Tolerability was excellent.
在本研究中，对一种新型缓释茶碱制剂的有效性和安全性进行了评估。20名患有支气管哮喘（平均年龄45岁）或慢性阻塞性肺疾病（平均年龄58岁）的患者（12名男性，8名女性）接受了该药物治疗。在30天的缓释茶碱治疗期间，所有患者均报告临床症状显著改善，肺功能测定数据（通气指标、肺内气体分布、通气控制、气体交换）证实了这一点。耐受性良好。
